These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16732624)

  • 1. [Positioning of PROactive and its clinical application in Japan--a new direction in diabetes care discussed by diabetology and circulatory disease specialists: discussion].
    Kawamori R; Kadowaki T; Daida H; Takeda N; Dormandy J
    Nihon Rinsho; 2006 Mar; 64(3):581-7. PubMed ID: 16732624
    [No Abstract]   [Full Text] [Related]  

  • 2. PROactive Study: (r)evolution in the therapy of diabetes?
    Ceriello A
    Diabet Med; 2005 Nov; 22(11):1463-4. PubMed ID: 16241907
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of glycemic control on the development of diabetic cardiovascular and kidney disease.
    Saha SA; Tuttle KR
    Cardiol Clin; 2010 Aug; 28(3):497-516. PubMed ID: 20621253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [How does the PROactive Study change therapy of diabetes?].
    Erdmann E
    MMW Fortschr Med; 2005 Oct; 147(41):6. PubMed ID: 16270501
    [No Abstract]   [Full Text] [Related]  

  • 5. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
    Szymborska-Kajanek A; Strojek K
    Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug safety. Planned study of Avandia in doubt after FDA review.
    Kean S
    Science; 2010 Jul; 329(5990):375. PubMed ID: 20651123
    [No Abstract]   [Full Text] [Related]  

  • 7. [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].
    Olsson AG
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2454-5. PubMed ID: 17002160
    [No Abstract]   [Full Text] [Related]  

  • 8. [Too positive comment on glitazones].
    Lindberg M
    Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
    [No Abstract]   [Full Text] [Related]  

  • 9. [Diabetes, heart, and glitazones].
    Philippe J
    Rev Med Suisse Romande; 2004 Mar; 124(3):133-5. PubMed ID: 15095655
    [No Abstract]   [Full Text] [Related]  

  • 10. [The effect of glitazones on the progression of type 2 diabetes and on cardiovascular endpoints].
    Schatz H
    Dtsch Med Wochenschr; 2005 Aug; 130(31-32):1825-30. PubMed ID: 16052448
    [No Abstract]   [Full Text] [Related]  

  • 11. PROactive: time for a critical appraisal.
    Betteridge DJ; DeFronzo RA; Chilton RJ
    Eur Heart J; 2008 Apr; 29(8):969-83. PubMed ID: 18375395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of thiazolidinedione use and cardiovascular risk: is it all about the sugar?
    Krantz MJ
    Pharmacotherapy; 2006 Jul; 26(7):1049; discussion 1049-50. PubMed ID: 16803430
    [No Abstract]   [Full Text] [Related]  

  • 13. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

  • 14. New drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications.
    McGuire DK; Inzucchi SE
    Circulation; 2008 Jan; 117(3):440-9. PubMed ID: 18212301
    [No Abstract]   [Full Text] [Related]  

  • 15. Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease.
    Harv Heart Lett; 2004 Mar; 14(7):1. PubMed ID: 15044139
    [No Abstract]   [Full Text] [Related]  

  • 16. Thiazolidinediones and slowing the progression of diabetes.
    Jackson T; Aquilina A; Bloom J; Guerra-Garcia H; Salom I; Tzeel A; Kaminsky R
    Manag Care Interface; 2007 Aug; 20(8):29-34. PubMed ID: 18041348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rough road for rosiglitazone.
    Goldfine AB
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic control and the heart: it matters how you get there.
    Bloomgarden Z
    J Diabetes; 2016 Jul; 8(4):453-4. PubMed ID: 26990043
    [No Abstract]   [Full Text] [Related]  

  • 19. Diabetes and heart failure: the role of thiazolidinediones in managing these partners in crime.
    Leier CV; Haas GJ
    J Am Coll Cardiol; 2007 Jul; 50(1):37-9. PubMed ID: 17601543
    [No Abstract]   [Full Text] [Related]  

  • 20. Rosiglitazone (Avandia) revisited.
    Med Lett Drugs Ther; 2010 Mar; 52(1333):17. PubMed ID: 20300053
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.